Marinomed Biotech AG
Vienna Stock Exchange MARI.VI
Marinomed Biotech AG Return on Equity (ROE) for the year ending December 31, 2023: 67.03%
-
Marinomed Biotech AG Return on Equity (ROE) for the year ending December 31, 2022 was 153.90%, a 105.00% change year over year.
-
Marinomed Biotech AG Return on Equity (ROE) for the year ending December 31, 2021 was -3,078.00%, a -2,643.79% change year over year.
-
Marinomed Biotech AG Return on Equity (ROE) for the year ending December 31, 2020 was -112.18%, a -68.91% change year over year.
-
Marinomed Biotech AG Return on Equity (ROE) for the year ending December 31, 2019 was -66.41%, a -189.31% change year over year.
| Date | Return on Equity (ROE) | Return on Capital Employed (ROCE) | Interest Coverage Ratio | Debt to Equity Ratio |
|---|
| CEO | Mr. Andreas Grassauer Ph.D. |
| IPO Date | Feb. 1, 2019 |
| Location | Austria |
| Headquarters | Hovengasse 25 |
| Employees | 36 |
| Sector | Health Care |
| Industries | |
Marinomed Biotech AG, a biopharmaceutical company, develops therapeutic products for indications in virology and immunology in Austria, other European countries, and internationally. Its products pipeline includes Budesolv for the treatment of allergic rhinitis and autoimmune gastritis; Tacrosolv, which is in Phase II clinical trial for anterior inflammatory eye diseases; Carravin for the treatment of nasal congestion; and Inhaleen that is in Phase I clinical trial for viral pneumonia, as well as Carragelose, which consists of nasal and throat sprays, and lozenges for treating viral respiratory infections. The company was formerly known as Marinomed Biotechnologie GmbH and changed its name to Marinomed Biotech AG in June 2017. Marinomed Biotech AG was incorporated in 2006 and is headquartered in Korneuburg, Austria.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email